NO2017021I1 - Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid - Google Patents

Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid

Info

Publication number
NO2017021I1
NO2017021I1 NO2017021C NO2017021C NO2017021I1 NO 2017021 I1 NO2017021 I1 NO 2017021I1 NO 2017021 C NO2017021 C NO 2017021C NO 2017021 C NO2017021 C NO 2017021C NO 2017021 I1 NO2017021 I1 NO 2017021I1
Authority
NO
Norway
Prior art keywords
calcite
time
ethyl
hydrochloride
salt
Prior art date
Application number
NO2017021C
Other languages
English (en)
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43527590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017021(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of NO2017021I1 publication Critical patent/NO2017021I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO2017021C 2009-07-29 2017-05-05 Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid NO2017021I1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US25581609P 2009-10-28 2009-10-28
US31363510P 2010-03-12 2010-03-12
PCT/US2010/043792 WO2011014707A2 (en) 2009-07-29 2010-07-29 Therapeutic agents for reducing parathyroid hormone levels

Publications (1)

Publication Number Publication Date
NO2017021I1 true NO2017021I1 (no) 2017-05-05

Family

ID=43527590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2017021C NO2017021I1 (no) 2009-07-29 2017-05-05 Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid

Country Status (30)

Country Link
US (10) US8999932B2 (no)
EP (5) EP3539555B1 (no)
JP (3) JP5270799B2 (no)
KR (1) KR101781841B1 (no)
CN (2) CN107674114B (no)
AU (1) AU2010278897B2 (no)
BR (1) BR112012002143B8 (no)
CA (1) CA2769525C (no)
CY (3) CY1118388T1 (no)
DK (2) DK2459208T3 (no)
ES (2) ES2729051T3 (no)
FR (1) FR17C1009I2 (no)
HK (1) HK1167108A1 (no)
HR (2) HRP20161614T1 (no)
HU (3) HUE030960T2 (no)
IL (1) IL217749A (no)
LT (3) LT2459208T (no)
LU (1) LUC00008I2 (no)
MX (1) MX2012001213A (no)
NO (1) NO2017021I1 (no)
NZ (1) NZ597922A (no)
PL (2) PL3192520T3 (no)
PT (2) PT2459208T (no)
RU (1) RU2557654C3 (no)
SG (2) SG10201406921SA (no)
SI (2) SI3192520T1 (no)
SM (1) SMT201700014B (no)
TW (1) TWI520744B (no)
WO (1) WO2011014707A2 (no)
ZA (1) ZA201200726B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
MX2012001213A (es) 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
HUE041362T2 (no) 2010-03-04 2019-05-28 Ea Pharma Co Ltd
EP2543660A4 (en) 2010-03-04 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
WO2011118843A1 (ja) 2010-03-24 2011-09-29 味の素株式会社 グルタミン酸エステル誘導体又はその塩
WO2011126099A1 (ja) 2010-04-02 2011-10-13 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
SI2717896T1 (sl) * 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
CA2854911C (en) * 2011-11-10 2019-09-24 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
CA2870711A1 (en) 2012-04-17 2013-10-24 Brown University Neuroprotective composition and method of use
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
CN114376970A (zh) 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
ES2786225T3 (es) 2014-04-03 2020-10-09 Amgen Inc Método para preparar AMG 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
JP6783787B2 (ja) * 2015-03-26 2020-11-11 アムジェン インコーポレイテッド エテルカルセチドの調製のための液相方法
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2018044468A1 (en) * 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
CN111601614A (zh) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 治疗和预防心脏病、心血管疾病及相关病症和症状的方法
CN111386109A (zh) 2017-12-20 2020-07-07 Ea制药株式会社 维持性透析下的继发性甲状旁腺功能亢进症的预防或治疗用医药组合物
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
WO2020204117A1 (ja) 2019-04-03 2020-10-08 Ｅａファーマ株式会社 安定性の良好な医薬組成物
MX2022006892A (es) * 2019-12-09 2022-10-07 Beijing Tuo Jie Biopharmaceutical Co Ltd Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
US20230223125A1 (en) * 2020-05-04 2023-07-13 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
CN115087662B (zh) * 2020-09-10 2023-09-26 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
WO2022257958A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
AU9131091A (en) * 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
WO1998004591A1 (en) 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US5895368A (en) 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
KR100351213B1 (ko) 1997-05-14 2002-09-05 아벤티스 파마슈티칼스 인크. 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물
BR9809138A (pt) * 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) * 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
EP2070911A2 (en) 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilized 1Alpha-Hydroxy vitamin D
DE10041126A1 (de) * 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
US6855693B2 (en) 2001-01-18 2005-02-15 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of δPKC
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
JP4310106B2 (ja) 2001-02-23 2009-08-05 ポリファー リミテッド 抗菌活性を有するテンプレート結合ペプチド擬似体
WO2003013543A1 (en) 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
US6790833B2 (en) * 2001-08-08 2004-09-14 The Research Foundation Of The State University Of New York Antifungal and antibacterial agents
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
US20040018976A1 (en) 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
AU2004291277A1 (en) 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
EP1699813A2 (en) 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
EP1781320A2 (en) * 2004-07-27 2007-05-09 Genzyme Corporation Use of thyrotropin for regeneration of bone
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
CA2621167A1 (en) 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
KR102274003B1 (ko) 2007-01-19 2021-07-08 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CA2701274A1 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
WO2009075773A2 (en) 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
MX2012001213A (es) 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
SI2717896T1 (sl) 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
CA2854911C (en) 2011-11-10 2019-09-24 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use

Also Published As

Publication number Publication date
IL217749A0 (en) 2012-03-29
US20200399309A1 (en) 2020-12-24
EP2459208A4 (en) 2014-06-04
TW201116290A (en) 2011-05-16
US10280198B2 (en) 2019-05-07
SMT201700014B (it) 2017-03-08
HUE043838T2 (hu) 2019-09-30
PT2459208T (pt) 2017-01-03
FR17C1009I2 (fr) 2019-04-12
EP2459208A2 (en) 2012-06-06
CY1121922T1 (el) 2020-10-14
EP3808363B1 (en) 2022-09-07
WO2011014707A2 (en) 2011-02-03
PL3192520T3 (pl) 2019-08-30
CN102711789B (zh) 2018-06-08
US20160159860A1 (en) 2016-06-09
PL2459208T3 (pl) 2017-05-31
EP3192520B1 (en) 2019-03-06
NZ597922A (en) 2015-01-30
MX2012001213A (es) 2012-06-12
BR112012002143B8 (pt) 2021-05-25
US20170114095A1 (en) 2017-04-27
PT3192520T (pt) 2019-06-12
US9567370B2 (en) 2017-02-14
RU2012107428A (ru) 2013-09-10
LUC00008I2 (no) 2017-05-30
EP3539555A1 (en) 2019-09-18
ZA201200726B (en) 2013-05-29
SG10201406921SA (en) 2014-11-27
CN107674114A (zh) 2018-02-09
CY2017010I1 (el) 2017-11-14
BR112012002143B1 (pt) 2020-12-08
JP5764613B2 (ja) 2015-08-19
EP3192520A1 (en) 2017-07-19
US20240116983A1 (en) 2024-04-11
US20120178688A1 (en) 2012-07-12
US20180022777A1 (en) 2018-01-25
US20150175664A1 (en) 2015-06-25
JP5270799B2 (ja) 2013-08-21
US8999932B2 (en) 2015-04-07
US20110028394A1 (en) 2011-02-03
EP4154900A1 (en) 2023-03-29
LTPA2017007I1 (lt) 2017-03-27
EP3808363A1 (en) 2021-04-21
HK1167108A1 (zh) 2012-11-23
ES2729051T3 (es) 2019-10-30
HRP20161614T1 (hr) 2017-02-24
JP2014094967A (ja) 2014-05-22
CN102711789A (zh) 2012-10-03
JP2013500990A (ja) 2013-01-10
TWI520744B (zh) 2016-02-11
CA2769525A1 (en) 2011-02-03
SI3192520T1 (sl) 2019-08-30
JP2013155195A (ja) 2013-08-15
CA2769525C (en) 2017-02-21
BR112012002143A2 (pt) 2016-11-08
LT2459208T (lt) 2017-02-27
KR20120104513A (ko) 2012-09-21
EP3539555B1 (en) 2020-12-30
AU2010278897B2 (en) 2015-02-26
IL217749A (en) 2016-09-29
HUS1700008I1 (hu) 2017-04-28
LTC2459208I2 (lt) 2021-07-12
SG178143A1 (en) 2012-03-29
RU2557654C2 (ru) 2015-07-27
US20190194252A1 (en) 2019-06-27
RU2557654C3 (ru) 2017-07-05
US9701712B2 (en) 2017-07-11
LT3192520T (lt) 2019-06-25
AU2010278897A1 (en) 2012-02-23
US9278995B2 (en) 2016-03-08
LUC00008I1 (no) 2017-03-16
CN107674114B (zh) 2022-10-25
HUE030960T2 (en) 2017-06-28
CY1118388T1 (el) 2017-06-28
DK2459208T3 (en) 2017-01-23
KR101781841B1 (ko) 2017-09-26
DK3192520T3 (da) 2019-05-27
SI2459208T1 (sl) 2017-04-26
ES2607954T3 (es) 2017-04-04
US8377880B2 (en) 2013-02-19
EP2459208B1 (en) 2016-09-28
US20130150297A1 (en) 2013-06-13
CY2017010I2 (el) 2017-11-14
HRP20190923T1 (hr) 2019-10-04
WO2011014707A3 (en) 2011-07-07
FR17C1009I1 (no) 2017-04-21

Similar Documents

Publication Publication Date Title
NO2017021I1 (no) Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid
NO2020001I1 (no) Gilteritinib eller et salt derav
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2021013I1 (no) filgotinib or a salt thereof
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2020039I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2017024I1 (no) Elosulfase alfa eller et farmasøytisk akseptabelt salt derav
NO2015012I1 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NO2017057I2 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2016016I2 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2017026I2 (no) Alektinib eller salt eller solvat derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2015014I1 (no) Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
DK2133672T3 (da) Fjerkrævægt
DE102009037898A8 (de) Greifeinrichtung
BRPI1006572A2 (pt) bombas
BRPI0911269A2 (pt) análogos de halicondrina b
NO2023002I1 (no) Lasmiditan or a pharmaceutically acceptable salt thereof
ATE546453T1 (de) Nalmefen-hydrochlorid-dihydrat